Vivoryon Net Income Per Share from 2010 to 2026

VVY Stock   1.38  0.02  1.43%   
Vivoryon Therapeutics Net Loss yearly trend continues to be comparatively stable with very little volatility. Net Loss will likely drop to -0.75 in 2026. From the period from 2010 to 2026, Vivoryon Therapeutics Net Loss quarterly data regression had mean square error of  0.16 and mean deviation of  0.58. View All Fundamentals
 
Net Loss  
First Reported
2010-12-31
Previous Quarter
(0.71)
Current Value
(0.75)
Quarterly Volatility
0.6748465
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Vivoryon Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vivoryon Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 127.7 K, Interest Expense of 59.2 K or Selling General Administrative of 8.3 M, as well as many indicators such as Dividend Yield of 0.0, Ptb Ratio of 7.18 or Book Value Per Share of 0.26. Vivoryon financial statements analysis is a perfect complement when working with Vivoryon Therapeutics Valuation or Volatility modules.
  
This module can also supplement various Vivoryon Therapeutics Technical models . Check out the analysis of Vivoryon Therapeutics Correlation against competitors.
The evolution of Net Income Per Share for Vivoryon Therapeutics NV provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Vivoryon Therapeutics compares to historical norms and industry peers.

Latest Vivoryon Therapeutics' Net Income Per Share Growth Pattern

Below is the plot of the Net Income Per Share of Vivoryon Therapeutics NV over the last few years. It is Vivoryon Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Vivoryon Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Net Income Per Share10 Years Trend
Slightly volatile
   Net Income Per Share   
       Timeline  

Vivoryon Net Income Per Share Regression Statistics

Arithmetic Mean(1.35)
Coefficient Of Variation(49.80)
Mean Deviation0.58
Median(1.12)
Standard Deviation0.67
Sample Variance0.46
Range1.9284
R-Value0.82
Mean Square Error0.16
R-Squared0.67
Significance0.000063
Slope0.11
Total Sum of Squares7.29

Vivoryon Net Income Per Share History

2026 -0.75
2025 -0.71
2024 -0.79
2023 -1.12
2022 -1.28
2021 -0.63
2020 -0.83

About Vivoryon Therapeutics Financial Statements

Vivoryon Therapeutics shareholders use historical fundamental indicators, such as Net Income Per Share, to determine how well the company is positioned to perform in the future. Although Vivoryon Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Vivoryon Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Vivoryon Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Net Loss(0.71)(0.75)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Vivoryon Stock Analysis

When running Vivoryon Therapeutics' price analysis, check to measure Vivoryon Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vivoryon Therapeutics is operating at the current time. Most of Vivoryon Therapeutics' value examination focuses on studying past and present price action to predict the probability of Vivoryon Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vivoryon Therapeutics' price. Additionally, you may evaluate how the addition of Vivoryon Therapeutics to your portfolios can decrease your overall portfolio volatility.